LCB84 / LigaChem Biosci, Mediterranea Theranostic, J&J - LARVOL DELTA

RigaChem Bio proves ADC technology with 1Q sales… Real growth begins [Google translation] (Medipana) - "According to the disclosure, sales in the first quarter of this year were 31,055.84 million won, a 305.6% increase compared to 7,658.04 million won in the same period last year...The reason why RigaChem Bio was able to increase sales equivalent to the previous year's performance in just one quarter was because of the signing of a technology transfer agreement for LCB84 (Trop2-ADC) with Janssen, a global pharmaceutical company, on December 22 last year....RigaChem Bio, which has multiple ADC pipelines, has confirmed that the safety data confirmed in the LCB14 clinical results has been proven again in the clinical results of other pipelines, including LCB71, and major pipelines, including LCB84, will also confirm clinical results in 2025."

Commercial • P1/2 data • Hematological Malignancies • Oncology • Solid Tumor

Preclinical evaluation of LCB84, a novel next-generation TROP2 directed ADC utilizing a cancer selective linker and an MMAE payload (AACR 2024) - "LCB84 demonstrates superior efficacy in mouse tumor xenograft studies when compared to benchmark TROP2-targeting ADCs, including sacituzumab govitecan and datopotamab deruxtecan. Additionally, LCB84 shows a stable preclinical pharmacokinetic profile with minimal loss of payload over time. The utilization of an ADC for target-mediated delivery, in combination with a stable beta-glucuronide trigger for selective payload release in tumors, allows for a superior preclinical therapeutic index which is expected to translate to a best-in-class ADC in the clinic."

Preclinical • Oncology • Solid Tumor • TACSTD2

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC (Businesswire) - "LegoChem Biosciences...announced on December 22 that it has entered into a license agreement with Janssen Biotech...to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC)....Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84. LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million, an option exercise payment of USD 200 million as well as potential development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. The companies will collaborate during the ongoing Phase 1/2 clinical trial, with Janssen solely responsible for clinical development and commercialization after option exercise."

Licensing / partnership • Solid Tumor

LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial (Businesswire) - "BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."

Diagnostic • Licensing / partnership • Oncology • Solid Tumor

LCB84: A Next-Gen TROP2 Targeting ADC Utilizing LegoChem Biosciences' Tumor Selective Linker (ADC-USA 2023) - "Sponsored by LCB LEGOCHEMBIO"

Oncology

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=300 | Recruiting | Sponsor: LegoChem Biosciences, Inc | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=300 | Not yet recruiting | Sponsor: LegoChem Biosciences, Inc

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor